The terms single, dual and triple refer to the number of receptor targets. Semaglutide targets GLP-1, tirzepatide targets GLP-1 and GIP, and retatrutide targets GLP-1, GIP and glucagon.
One, two or three receptor targets
The classification answers a mechanism question. Weight change and tolerability are separate clinical questions and require comparative evidence with common measurements.
How to interpret the evidence
A comparison table should put receptor targets and clinical evidence in separate columns. This keeps a count of targets from being mistaken for a clinical ranking.
Start with the intervention name and receptor targets, then follow the links to the original trial if you want to check what was measured in people.